OECD GLP ties facility status to inspections and study audits
The OECD principles define a managerial quality-control system for covered non-clinical safety studies, while national programmes verify facility compliance through inspections and study audits. A platform cannot self-declare that status.
Editorial figure by Lab Systems Index. Source context: OECD Good Laboratory Practice and compliance monitoring.
GLP defines an organizational evidence chain
The OECD description follows a study from planning through performance, monitoring, recording, reporting, and retention. That sequence gives informatics buyers a concrete record test: the system should preserve the authorized protocol, responsible roles, contemporaneous data, changes, quality-assurance activity, report state, and archive disposition without collapsing them into one final document.
Each artifact needs identity, version, author or actor, time, study context, approval state, and lineage. A data platform can make those relationships reviewable, but an immutable-storage claim or electronic signature feature alone does not establish that the study was organized and conducted under the applicable GLP authority.
Roles stay connected but noninterchangeable
OECD names test-facility management, the study director, study personnel, and quality-assurance personnel as distinct responsibility holders. Software should support the handoffs among them while preserving who originated, reviewed, inspected, corrected, and approved each record. A universal administrator role or shared approval queue can erase the separation the study history needs to show.
A useful demonstration should include a protocol change, a quality-assurance observation, the communication and disposition of that observation, and the final-report review. It should prevent a person from silently rewriting an earlier state and should retain the original observation even when a correction is accepted.
Scope depends on study purpose and jurisdiction
The OECD page centers non-clinical health and environmental safety studies submitted to receiving authorities and says human-subject studies are outside this GLP scope. It lists several test-item categories and notes that jurisdictions may extend the principles to other regulated products, such as medical devices. A laboratory name or instrument type cannot determine applicability.
Systems should retain the study purpose, test item, receiving authority, jurisdiction, applicable GLP basis, sponsor decision, and qualified scope review. The same platform may hold research, quality-control, clinical, and regulated non-clinical records, but their presence in one repository must not confer one regulatory status on all of them.
Compliance monitoring is not scientific validation
OECD says national programmes verify GLP compliance through facility inspections and study audits. That status concerns operation under the principles. It does not, without separate scientific and regulatory review, prove that a method is fit, a hypothesis is correct, a result is reproducible, or a receiving authority will accept a particular conclusion.
Lab Systems Index separates organizational integrity, system validation, method suitability, scientific interpretation, and submission acceptance. Buyers should require evidence for each claimed layer and avoid dashboards that translate a facility or study GLP status into a green scientific-validity badge.
Enterprise buyer test
Translate this change into the exact population, record type, workflow stage, decision owner, effective date, and evidence that could be affected. Ask current or prospective providers to demonstrate the named workflow with representative data and an exception—not a polished feature tour. Record what official documentation establishes, what a provider states, what the team observes, and what remains unresolved.
A defensible review also identifies the dependency outside the product. Authority interpretation, policy configuration, data quality, integrations, human judgment, approval rights, release governance, training, and retained evidence may remain customer or service responsibilities. The evaluation should preserve those boundaries instead of treating a technology claim as the complete operating model.
What we will watch next
Lab Systems Index will watch the named source and affected market records for later evidence that changes status, scope, availability, implementation timing, workflow consequence, or the limits of the initial report. A later announcement does not silently overwrite this dated account; the change ledger preserves the sequence.